Chemistry:Delequamine
From HandWiki
Delequamine (INN; developmental code names RS-15385, RS-15385-197) is a potent and selective α2-adrenergic receptor antagonist which was under development for the treatment of erectile dysfunction and major depressive disorder but was never marketed.[1][2][3][4]
It is structurally related to the naturally occurring α2-adrenergic receptor antagonist yohimbine but has greater selectivity in comparison.[3][4] The drug has been found to affect sexual function and sleep in humans.[4]
Delequamine reached phase 3 clinical trials prior to the discontinuation of its development.[1] The drug was under development in the 1990s and its development was discontinued by 1999.[1] It was first described in the scientific literature by 1990.[5]
See also
References
- ↑ 1.0 1.1 1.2 "Delequamine". AdisInsight. Springer Nature Switzerland AG. 22 September 1999. https://adisinsight.springer.com/drugs/800004435.
- ↑ Dictionary of Pharmacological Agents. Taylor & Francis. 1996. ISBN 978-0-412-46630-4. https://books.google.com/books?id=Z_mfTTIApVEC. Retrieved 21 October 2024.
- ↑ 3.0 3.1 "Pharmacological Therapy for the Treatment of Erectile Dysfunction". Annual Reports in Medicinal Chemistry. Annual Reports in Medicinal Chemistry. 34. Academic Press. 1999. p. 78. ISBN 978-0-08-058378-5. https://books.google.com/books?id=pJ1TIGO9VVYC&pg=PA78. Retrieved 21 October 2024.
- ↑ 4.0 4.1 4.2 "Effects of alpha-2 blockade on sexual response: experimental studies with Delequamine (RS15385)". International Journal of Impotence Research 12 (S1): S64-S69. March 2000. doi:10.1038/sj.ijir.3900507. PMID 10849567.
- ↑ "RS-15385-197, a potent andselective alpha2-adrenoceptor antagonist.". British Journal of Pharmacology 99: 123P. 1990. https://scholar.google.com/scholar?cluster=6701996947549813409.
 |  |
